Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2009-06-30

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatitis C virus infection is the most common blood-borne infection in the United States and is a leading cause of chronic liver disease affecting 130 million people around the world. It is estimated that 1.6% of the US population may be affected by Hepatitis C infection. The only recommended treatment that has been approved for your condition is the use of interferon and ribavirin. In patients with chronic Hepatitis C, there tends to be an accumulation of fat in the liver. Fatty liver has been associated with failure of treatment.

The accumulation of fat in the liver has been blamed on a particular type of fat called triglycerides. Fish oil, by reducing a type of fat called VLDL, can lower the triglyceride concentration by as much as 50 percent or more. This study seeks to determine if the administration of fish oil along with standard treatment to patients with Hepatitis C will increase the treatment response rates.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

NCT01285362

Non-Alcoholic Fatty Liver Disease

COMPLETED NA

Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)

NCT00681408

Non-alcoholic Steatohepatitis Fatty Liver

COMPLETED PHASE2/PHASE3

Effect of Omega-3 PUFA Supplementation in NAFLD Patients

NCT00230113

Non-Alcoholic Fatty Liver Disease

COMPLETED PHASE2

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

NCT00504309

Hypertriglyceridemia

COMPLETED NA

Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers

NCT05121766

COVID-19

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatic steatosis may be present in up to 66% of cases of chronic Hepatitis C infection. Previous studies have reported steatosis to be an independent predictor of treatment failure in patients with chronic hepatitis C infection.

The pathogenesis of hepatic steatosis in chronic Hepatitis C infection has not been fully elucidated. Hepatic steatosis is a manifestation of excessive triglyceride accumulation in the liver. Hypertriglyceridemia may benefit from Omega-3 fatty acid (fish oil supplements) which, by reducing VLDL production can lower the serum triglyceride concentration by as much as 50 percent or more.

The treatment of chronic hepatitis C results in an average sustained viral response rate of 54%-63%. We have found response rates of around 50% on treatment of patients. We hypothesize that by giving omega-3 fatty acids along with interferon therapy for patients with Hepatitis C, we may be able to increase the treatment response rates. Thus, the purpose of the study is to look at the effect of omega 3 fatty acids on early and sustained viral response rates in patients with chronic HCV infection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1.

Omega-3 Fatty Acids 4 grams/day

Group Type EXPERIMENTAL

Omega-3 Fatty Acids

Intervention Type DIETARY_SUPPLEMENT

Omega-3 Fatty Acids - 4 grams per day

2.

Placebo comparator along with interferon.

Group Type PLACEBO_COMPARATOR

Placebo comparator

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Omega-3 Fatty Acids

Omega-3 Fatty Acids - 4 grams per day

Intervention Type DIETARY_SUPPLEMENT

Placebo comparator

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Omacor@

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients \> 18 years of age
* Patients with chronic hepatitis C infection
* Patients receiving interferon for treatment of hepatitis C

Exclusion Criteria

* pregnant or lactating patients
* End stage target organ damage in diabetes mellitus: advanced renal failure (serum creatinine \>2.0 mg/dl) with or without dialysis, severe neuropathy, advanced peripheral vascular disease.
* Anticipated life expectancy less than 2 years
* Co-existent etiologies for liver disease
* Alcohol consumption more than 30 g per day in men and more than 20 g per day in women.
* Patients on Omega-3 fatty acid supplementation or those patients who report eating oily fish such as salmon, albacore tuna, sardines, etc. twice a week or more frequently.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No